Brødkrumme Forside Iconic Therapeutics Iconic Therapeutics Iconic Therapeutics targets Tissue Factor (TF) in angiogenesis, inflammation, cell growth and metastasis to treat ophthalmologic, oncologic, and autoimmune diseases. Is in Phase II clinical trials in wet-AMD. Related news about Iconic Therapeutics Iconic Therapeutics Initiates Second Phase 2 Study of ICON-1 in Patients with Neovascular (wet) AMD Iconic Therapeutics Appoints Brandon Smith Chief Operating Officer Leadership Team Strengthened for Development and Partnering ICONIC THERAPEUTICS APPOINTS JULIA P. GREGORY TO BOARD OF DIRECTORS ICONIC THERAPEUTICS TO PRESENT PHASE 2a EMERGE TRIAL RESULTS AT MIAMI MEETING Iconic Therapeutics Announces Final Close of Series C Financing With Additional $10 Million Investment Iconic Therapeutics' website Lundbeckfonden BioCapital Investeringsår 2014 Lokation San Francisco, California, USA
